Harada Hironori

Affiliation and department：

Research field (1)： Hematology and oncology

Research theme for competitive and other funds (27)：

2024 - 2027 急性巨核芽球性白血病治療薬開発のための包括的な白血病細胞分化停止機構解析
2022 - 2025 血液がん発症におけるミトコンドリア断片化と炎症性シグナル経路活性化のクロストーク
2022 - 2024 免疫担当細胞に着目したがん悪液質病態の発症機序解明と新規治療戦略の構築
2020 - 2023 Molecular diagnosis of myeloid neoplasms using targeted gene panel
2019 - 2023 Comparative Study on the Issues of Nuclear Global Disasters from the Viewpoint of Life, Livelihood and Mind

2019 - 2023 Functional analysis of CCDC26, a noncoding RNA related to myeloid leukemia, and search of a target for treatment of tumor

2019 - 2022 Molecular mechanisms of lower-risk MDS

2016 - 2019 Molecular pathogenesis of familial myelodysplastic syndromes

2015 - 2019 International comparative study of nuclear disasters in Semipalatinsk, Chernoby, Hiroshima/Nagasaki and Fukushima

2015 - 2018 Overexpression of RUNX1 short isoform induced by epigenetic dysregulation in the development of myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

2014 - 2018 Study of the radiation fallout around the former Soviet Union Semipalatinsk nuclear test site - Dosimetry and health effects -

2013 - 2016 Molecular mechanisms of radiation-associated myelodysplastic syndromes (MDS)

2013 - 2015 RUNX1とエピジェネティック制御機構破綻の協調作用によるMDS発症機構の解明

2012 - 2015 Social medical study of late effect of radiation exposure on young persons

2012 - 2015 The function of the novel noncoding RNA related to the growth control of myeloid leukemia cells

2012 - 2015 Molecular mechanisms of myelodysplastic syndromes (MDS) using RUNX1-mutated iPS cells derived from familial MDS patients

2011 - 2014 Research on the radiation exposure among inhabitants near the Semipalatinsk Nuclear Test Site

2011 - 2013 RUNXファミリーの異常による細胞分化制御破綻と新たなMDS発症機構の解明

2010 - 2012 Molecular mechanism of the therapy-related myeloid neoplasms

2009 - 2011 Establishment of new classification in myeloid neoplasms for personalized medicine

2008 - 2010 Human Effects in Inhabitants near the Semipalatinsk Nuclear Test Site

2007 - 2008 AML1 point mutations play a pivotal role in the pathogenesis of MDS/AML

2006 - 2007 Genetic pathway in molecular pathogenesis of myelodysplastic syndrome (MDS) with AML1 point mutations

2005 - 2006 Genetic pathway in molecular pathogenesis of myelodysplastic syndrome

2003 - 2004 Proteomic analysis of AML1/RUNX1 mutant complexes

2002 - 2002 原爆被爆者の骨髄異形成症候群(MDS)

2000 - 2001 赤血球分化における血球特異的RINGフィンガー蛋白、HERF1の分子生物学的役割

Show all

Papers (141)：

Yasutaka Masuda, Daichi Sadato, Takashi Toya, Yuzuru Hosoda, Chizuko Hirama, Hiroaki Shimizu, Yuho Najima, Hironori Harada, Yuka Harada, Noriko Doki. Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients. International journal of hematology. 2025
Yasutaka Masuda, Daichi Sadato, Takashi Toya, Chizuko Hirama, Hiroaki Shimizu, Yuho Najima, Hironori Harada, Yuka Harada, Noriko Doki. Telomere shortening in donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation: a case report. Annals of hematology. 2025
Yusuke Uchibori, Shuhei Kurosawa, Yuho Najima, Kyoko Haraguchi, Daichi Sadato, Chizuko Hirama, Yasutaka Sadaga, Kaori Kondo, Chika Kato, Satoshi Sakai, et al. Changes in donor lymphocyte infusion for relapsed patients post-hematopoietic stem cell transplantation: a 30-year single-center experience. Frontiers in immunology. 2025. 16. 1521895-1521895
Hirotaka Matsui, Minori Koizumi, Rei Kudo, Akiko Nagamachi, Masahiko Ajiro, Hironori Harada, Yuka Harada, Shigeyuki Shichino, Akihide Yoshimi. Pathogenic Significance of the DDX41 p.R525H Variant Revealed By Single-Cell RNA-Seq Analysis. Blood. 2024. 144. Supplement 1. 5719-5719
Fumihiko Ouchi, Naoki Shingai, Yuho Najima, Daichi Sadato, Chizuko Hirama, Satoshi Wakita, Kaori Kondo, Yasutaka Sadaga, Chika Kato, Satoshi Sakai, et al. Quizartinib with donor lymphocyte infusion for post-transplant relapse of FLT3-ITD-positive acute myeloid leukemia. International journal of hematology. 2024

ｍore...

MISC (181)：

田辺季佐, 名島悠峰, 井ノ口卓彦, 遠藤麻惠, 西尾優子, 貞任大地, 神原康弘, 熱田雄也, 小沼亮介, 安達弘人, et al. 胚細胞腫瘍の治療後に続発したinv(16)を伴う急性骨髄性白血病発症を契機に診断されたKlinefelter症候群. 臨床血液. 2022. 63. 7. 746-752
酒井知史, 清水啓明, 貞任大地, 平間千津子, 神原康弘, 小沼亮介, 和田敦司, 内堀雄介, 尾内大志, 西島暁彦, et al. TKIに抵抗性を示し、同種移植後早期にCNS再発を認めたCMLの1例. 臨床血液. 2022. 63. 5. 497-497
林嘉宏, 原田浩徳. ミトコンドリア異常による骨髄異形成症候群の発症機序. 血液内科. 2022. 84. 3. 375-380
新谷直樹, 貞任大地, 原田浩徳, 大橋一輝, 原田結花, 土岐典子. フェリチン上昇を伴う骨髄異形成症候群(MDS)の臨床・細胞遺伝学的検討. 日本内科学会雑誌. 2022. 111. 臨増. 183-183
加藤千賀, 名島悠峰, 貞任大地, 貞任大地, 平間千津子, 平間千津子, 酒井知史, 神原康弘, 小沼亮介, 熱田雄也, et al. Venetoclax-based salvage therapy before and after allogeneic stem cell transplantation for AML. 日本造血・免疫細胞療法学会総会プログラム・抄録集. 2022. 44th

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page